- Home
- HBT vs MNKD Comparison
HBT vs MNKD Comparison
Compare HBT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | MNKD |
|---|---|---|
| Founded | 1920 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | HBT | MNKD |
|---|---|---|
| Price | $35.68 | $4.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $30.75 | $8.69 |
| AVG Volume (30 Days) | 129.7K | ★ 4.5M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $35.73 | $35.81 |
| Revenue Next Year | $7.01 | $11.89 |
| P/E Ratio | $32.08 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $22.36 | $2.23 |
| 52 Week High | $37.51 | $6.51 |
Technical Indicators
Market Signals| Indicator | HBT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 54.22 |
| Support Level | $35.34 | $3.74 |
| Resistance Level | $37.17 | $4.55 |
| Average True Range (ATR) | 0.73 | 0.19 |
| MACD | -0.25 | 0.03 |
| Stochastic Oscillator | 41.90 | 69.45 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.